Trial of Argon Plasma Coagulation Versus APC and APC and Hemospray in the Treatment of Radiation Proctitis
NCT ID: NCT02233933
Last Updated: 2014-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2014-09-30
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison Between Two Different Parameters of Argon Plasma Coagulation in the Treatment of Chronic Radiation Proctitis: Historical Control Trial.
NCT02104271
Trial of Endoscopy Bipolar and Argon of Chronic Rectal Bleeding From Radiation Telangiectasias
NCT00725244
Combined Therapy in Radiation Proctopathy
NCT01613534
Micronized Purified Flavonoid- Fraction (MPFF) in the Management of Radiation Proctitis
NCT04335617
CryoSpray Ablation(TM)to Determine Safety and Feasibility in Radiation Induced Proctitis
NCT00756197
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
argon plasma coagulation
argon plasma coagulation of radiation proctitis
Hemospray
hemospray is used after argon coagulation to stop bleeding
argon plasma coagulator and hemospray
treatment of radiation proctitis with argon plasma coagulator followed by application of hemospray
Hemospray
hemospray is used after argon coagulation to stop bleeding
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hemospray
hemospray is used after argon coagulation to stop bleeding
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
British Columbia Cancer Agency
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alan Weiss
Principal Investgator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alan A Weiss, MD
Role: PRINCIPAL_INVESTIGATOR
BCCA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
British Columbia Cancer Clinic
Vancouver, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RadP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.